Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

Centre for Addiction and Mental Health (Toronto)

$105,000.00

The effects of an IL-1R antagonist in a rodent model of postpartum depression and offspring stress resiliency

EF 2023-24

Résumé
Depression affects twice as many females than males. Notably, it is during periods of hormonal shifts that females experience a heightened risk for depression. One such time is the postpartum period which occurs after giving birth. In Canada, approximately 23% of mothers who give birth develop postpartum depression (PPD) and the risk of PPD increased during the COVID-19 pandemic. During the postpartum the brain and body undergo massive changes that play a role in depression onset. People that are depressed often have a smaller brain region known as the hippocampus. In the postpartum, we see marked decreases in neuroplasticity (the brains ability to form and make new connections) and increases in inflammation. Further, antidepressant treatments that target the serotonergic system can be beneficial in improving depression symptoms. However, these benefits are rarely seen in PPD. Additionally, children of mothers with PPD show an increased risk of mental illness themselves. Thus, there is an urgent need to develop better therapies to treat PPD to benefit both mother and child. Current research has outlined increased inflammation is a potential culprit for the decreased efficacy of antidepressants in the postpartum. To determine the involvement of inflammation in treatment efficacy in PPD, we administered a drug that reduces the effects of inflammation along with serotonin treatment in a rodent model of PPD. To measure efficacy we will measure depressive-like behaviours, and associated brain changes (inflammation and neuroplasticity). We also examined the offspring of PPD mothers, and looked at how maternal treatments altered the ability of offspring to be resilient to stress later in adult males and females. This project will study why we see decreased antidepressant efficacy in PPD and may promote new types of treatment. Very few studies examine the influence of PPD or how this might affect stress resilience in offspring, our studies aim to fill this knowledge gap.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Emplacement
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
497176
Name
Garcia de leon Montano Romina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The effects of an IL-1R antagonist in a rodent model of postpartum depression and offspring stress resiliency
Programtype2
Studentship Programs
Orgnameinp2
Centre for Addiction and Mental Health (Toronto)
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Antidepressant Efficacy; Biomarker Quantification; Immunohistochemistry; Major Depressive Disorder; Neuroimmunology; Neuroplasticity; Postpartum Depression; Rat Behaviour; Sex Differences; Stress
Abstract
Depression affects twice as many females than males. Notably, it is during periods of hormonal shifts that females experience a heightened risk for depression. One such time is the postpartum period which occurs after giving birth. In Canada, approximately 23% of mothers who give birth develop postpartum depression (PPD) and the risk of PPD increased during the COVID-19 pandemic. During the postpartum the brain and body undergo massive changes that play a role in depression onset. People that are depressed often have a smaller brain region known as the hippocampus. In the postpartum, we see marked decreases in neuroplasticity (the brains ability to form and make new connections) and increases in inflammation. Further, antidepressant treatments that target the serotonergic system can be beneficial in improving depression symptoms. However, these benefits are rarely seen in PPD. Additionally, children of mothers with PPD show an increased risk of mental illness themselves. Thus, there is an urgent need to develop better therapies to treat PPD to benefit both mother and child. Current research has outlined increased inflammation is a potential culprit for the decreased efficacy of antidepressants in the postpartum. To determine the involvement of inflammation in treatment efficacy in PPD, we administered a drug that reduces the effects of inflammation along with serotonin treatment in a rodent model of PPD. To measure efficacy we will measure depressive-like behaviours, and associated brain changes (inflammation and neuroplasticity). We also examined the offspring of PPD mothers, and looked at how maternal treatments altered the ability of offspring to be resilient to stress later in adult males and females. This project will study why we see decreased antidepressant efficacy in PPD and may promote new types of treatment. Very few studies examine the influence of PPD or how this might affect stress resilience in offspring, our studies aim to fill this knowledge gap.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Garcia de leon Montano, Romina
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~